LINK Medical has announced the integration of Pharm Assist into the LINK Medical family. “We are very excited to have Pharm Assist integrate with our network of expert teams, especially
Nordic Life Science
NOT A SUBSCRIBER? SIGN UP TODAY AND GET THE FULL LIFE SCIENCE PICTURE
ONLY 13 €/MONTH
NLS News
Orion and Bayer further expand the global clinical development program for the oral androgen receptor inhibitor (ARi) darolutamide in prostate cancer. The new Phase III clinical study, ARASTEP, will investigate
Advertisement
Calquence, a next generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received
The agreement covers Remedium’s lead candidate, a disease-modifying treatment for Osteoarthritis (OA) under the name RMD 1101. Biovian has agreed to include Remedium’s lead candidate in Biovian’s AAV manufacturing platform
What if we could silence certain genes to treat a wide range of medical conditions, from genetic conditions to infectious diseases, and even cancer? It may sound like science fiction,
In order to strengthen the company’s liquidity and to ensure the continued development of the company’s pipeline, on July 27, 2022 the Aqilion Board of Directors decided on to carry
In the report “The scientific impact of Danish research 1980-2020,” the researchers behind the study state that the scientific impact of Danish research has been on the decline for a
Innovation Fund Denmark (Innovationsfonden) has awarded its largest grant for research and development of photothermal therapy to a consortium of four academic groups and FluoGuide. The grant valued at DKK
The company has received a GMP manufacturing license and a certificate of GMP compliance from the Swedish Medical Products Agency, which means that the company can produce at scale for
The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of patients with metastatic hormone-sensitive prostate cancer
Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in
Cancer Crosslinks 2023 was a day of inspiration, insights, and interactions for professionals from across the cancer field in Norway and beyond. The 15th Cancer Crosslinks was held in Oslo
For six months, starting in January 2023, Sweden has the Presidency of the Council of the European Union. It is much more than an honorary role, encompassing an opportunity for
Novo Nordisk has announced it is lowering the US list prices of several insulin products by up to 75% for people living with type 1 and type 2 diabetes. Products
Sponsored content
Spot-checking measurements of environmental conditions
Spot-checking is a less time-consuming process than calibration, in part because the calibration process can include as-found data, adjustment (if necessary), and as-left data whereas spot-checking is a verification that the unit under test is still within specification.
Drug and Device Development
Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee
Affibody has announced that data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be
Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in
The company has announced that the first patient was dosed in a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy,
Calliditas Therapeutics has announced results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy.
Profile
The philosophical aspect of chemistry led Morten Meldal to the field and he loves, and cannot help thinking about, the next solution and the intriguing questions about our being and
Iris Öhrn considers herself a cosmopolitan person, and with good reason. The investment advisor for life science at Business Region Göteborg left her native Cuba to study and work abroad
Massachusetts Institute of Technology (MIT) in the US has produced more than its share of engineers and computer scientists, but unlike many of his peers, alumnus Dr. Robert Langer, ScD,
Careers
Isa Lindgren has been intrigued by all things science since she was a child. As Manager of Analytical Development at NorthX Biologics she gets to integrate her fascination with a
SwedenBIO has appointed the co-founder and operational manager of Sprint Bioscience, Jessica Martinsson, as its new Director General. “With her entrepreneurial experience and co-founder of a life science company, SwedenBIO
Evaxion Biotech has announced that its new Chief Executive Officer (CEO) Per Norlén has joined the company on October 3rd. “With Per at the steering wheel, we expect to bring
Careers
Jennie Ekbeck, CEO at Umeå Biotech Incubator, has been appointed Innovations Angel of 2015. With her drive and problem-solving mindset she wants to make exciting research into business ideas and
JOB ALERTS
Read the latest issue of our magazine!
No 01 2023 // The major theme in this issue is Life Sciences for a Better World, highlighting both global and Nordic efforts being done within the fields of the Environment, Global health, Social responsibility and Peace. We take for example a closer look at the status of clinical trials in the Nordic region and the risks of APIs in the Baltic Sea region, we learn more about a company’s possibilities to increase its social impact and why academic freedom is so closely linked to democracy.
Our profiles in the issue are Nobel Laureate Carolyn Bertozzi, and Jónas Einarsson, CEO of Radforsk. They both share their inspiring journeys as well as their choices and passions in life.
This, and much more, in our latest issue – out now!
Venture Capital
Nordic Life Science asked Fredrik Dahl, co-founder at Colibri Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges Nordic life science
Nordic Life Science asked Claus Andersson, General Manager at Sunstone Life Science Venture, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
Nordic Life Science asked Inka Mero, Founder and Managing Partner at Voima Ventures, what Nordic venture capitalists are looking for today within life sciences and what current opportunities and challenges
“Start by asking what the problem is that you are trying to solve and develop the technology, team, and plan to solve that problem – not what you can do with the technology.” – Fredrik Dahl, Colibri Ventures
Upcoming events
Meet your next strategic partner at Europe’s largest springtime partnering event. This year’s event will be arranged as an in-person event in Basel, Switzerland, March 20-22, and a digital event,
Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting healthcare innovations, investor and industry. Swiss Nordic Bio in Zurich is a high-level partnering and investor event
Meet decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, and investment firms throughout Europe. Learn from major investment firms about the
As Precision Medicine initiatives around the world gather pace, the Nordic countries are in an enviable position when it comes to joining all the dots. The link between digital health,
The latest research news from the Nordic region
Science articles
Henrik Toft Sørensen, Professor of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, is receiving the 2023 prize, accompanied by 1.5 million DKK. He receives the Prize in recognition of
Findings from the major study iStopMM has been used to redefine monoclonal gammopathy of undetermined significance (MGUS), a precursor to multiple myeloma. We spoke with Þórir Einarsson Long, one of
An international team of researchers have combined ideas from biology, computer science and mathematics to explain why evolution seems to favor symmetry. We spoke with Iain Johnston, a professor at
Thanks to a donation of SEK 35 million from financier and philanthropist Rune Andersson, Karolinska Institutet’s research group leader Andrea Carmine Belin will very soon be setting up the world’s
Olink Holding has announced the 2022 winner of the young researchers’ award, Novelties in Biomarkers, Maria Martin-Grau at the University of Valencia, Spain. Novelties in Biomarkers is an annual award
The European Patent Office (EPO) has honoured Hungarian-American researcher Katalin Karikó with the European Inventor Award 2022 in the category “Lifetime achievement”, for her seminal work in developing modified messenger
Nordic Life Science
The latest clinical trials
Affibody has announced that data from treatment with izokibep in the open label part (Part A) of a Phase 2b/3 trial in patients with moderate-to-severe Hidradenitis Suppurativa (HS) will be
Targovax has announced that the first patient has been dosed with cancer vaccine TG01 in the combination study with PD-1 checkpoint inhibitor (CPI) balstilimab in mutant RAS pancreatic cancer in
The company has announced that the first patient was dosed in a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy,
Calliditas Therapeutics has announced results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy.
The company has announced the completion of the patient enrollment in the company’s phase 3 clinical study SPARKLE with the lead candidate drug Orviglance. “We are very pleased to have
The company has reported favorable safety and promising early signs of efficacy following an initial analysis of the phase Ib part of the clinical trial TRIFOUR. In collaboration with the
Modus Therapeutics has announced positive top-line data from its lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis
The company has announced topline data from BGBC008, a phase 2 trial evaluating its lead compound bemcentinibin combination with MSD’s anti-PD-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC)
Guard Therapeutics have announced that 134 of the planned 268 patients have been dosed in the global randomized, double-blinded and placebo-controlled Phase 2 clinical trial (AKITA). The AKITA study has
Sign up to our newsletter